These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35657580)

  • 1. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
    Navarrete-Rouco ME; Luque S; Sorlí L; Benítez-Cano A; Roberts JA; Grau S
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):561-566. PubMed ID: 35657580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
    Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
    Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature.
    Sheffield M; Nelson D; O'Neal M; Gould AP; Bouchard J; Nicolau D; Justo JA; Hucks J; Bookstaver PB
    Int J Antimicrob Agents; 2020 Nov; 56(5):106158. PubMed ID: 32919007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
    Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
    Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
    Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B
    Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
    Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
    Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.
    Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
    Montero MM; Domene-Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer-Alapont L; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Sci Rep; 2021 Nov; 11(1):22178. PubMed ID: 34773066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
    Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
    Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
    Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.